Advances in myeloid leukemia treatment have changed both acute and chronic forms of the disease. For chronic myeloid leukemia (CML), daily targeted tablets now give most patients a near-normal life expectancy. For acute myeloid leukemia (AML), intensive chemotherapy is still the backbone for fit patients, but it is increasingly combined with drugs aimed at specific mutations, and gentler combinations have opened effective treatment to older adults who could not tolerate chemotherapy before.
This article summarizes current strategies and future perspectives in plain terms, for patients, caregivers, and students. For the wider journey from diagnosis onward, see our overview of leukemia diagnosis and advanced treatment strategies, or the main leukemia guide.
What Is Myeloid Leukemia?
Myeloid leukemia is a cancer of the cells in the bone marrow that normally mature into red cells, platelets, and most white cells. A genetic change makes these cells multiply out of control. In the acute form, immature cells called blasts build up rapidly and crowd out normal blood production. In the chronic form, the cells still mature but are overproduced, and the disease progresses slowly.
The result in both is a form of bone marrow failure: anemia causing fatigue, low platelets causing bruising and bleeding, and a lack of working white cells causing infections. Like other hematologic cancers, its treatment depends on a precise diagnosis.
Why Molecular Testing Now Drives Treatment
Modern treatment starts in the laboratory. After a blood count and bone marrow biopsy, specialists use flow cytometry, cytogenetics, and next-generation sequencing (NGS) to identify the leukemia’s chromosome changes and gene mutations. In CML, the defining finding is the Philadelphia chromosome, which creates the BCR-ABL1 fusion gene.
In AML, results such as FLT3, NPM1, IDH1, IDH2, and TP53 mutations place a patient in a favorable, intermediate, or adverse risk group. They also decide whether a targeted drug should be added. For this reason, results from genetic testing are now often awaited, where it is safe, before choosing the full treatment plan.
Current Strategies for Acute Myeloid Leukemia
AML treatment is usually divided into induction, which aims for remission, and consolidation, which aims to keep it. The approach depends on the patient’s fitness and the leukemia’s genetic profile.
| Approach | Examples | Typically used for |
|---|---|---|
| Intensive chemotherapy | Cytarabine plus an anthracycline (“7+3”) | Fit patients, usually younger adults |
| FLT3 inhibitors | Midostaurin, quizartinib, gilteritinib | AML with FLT3 mutations |
| IDH inhibitors | Ivosidenib (IDH1), enasidenib (IDH2) | AML with IDH mutations |
| Antibody-drug conjugate | Gemtuzumab ozogamicin (targets CD33) | Selected favorable-risk AML |
| Lower-intensity combination | Venetoclax with azacitidine or decitabine | Older or less fit patients |
| Differentiation therapy | All-trans retinoic acid plus arsenic trioxide | Acute promyelocytic leukemia (APL) |
| Allogeneic stem cell transplant | Donor stem cells after conditioning | Intermediate or high-risk AML in remission |
The venetoclax combination is one of the biggest practical advances of recent years. Venetoclax blocks BCL-2, a protein leukemia cells use to avoid dying, and pairing it with a hypomethylating agent gives many older patients a real chance of remission. APL, a special subtype, is now treated largely without conventional chemotherapy and is among the most curable leukemias.
Current Strategies for Chronic Myeloid Leukemia
CML was the first cancer transformed by a targeted drug. Tyrosine kinase inhibitors (TKIs) block the BCR-ABL1 protein that drives the disease. Imatinib was the first, followed by dasatinib, nilotinib, and bosutinib, with ponatinib and asciminib used when there is resistance or intolerance.
Response is tracked by measuring BCR-ABL1 levels in the blood with a sensitive PCR test. Patients who achieve a deep and sustained molecular response may be able to stop treatment under close monitoring, an approach called treatment-free remission. If levels rise again, restarting the TKI usually brings the disease back under control. Transplant is now reserved for the few patients whose disease resists several TKIs or progresses to an advanced phase.
Supportive Care Still Matters
Good supportive care makes intensive treatment possible. It includes red cell and platelet transfusions, antibiotics and antifungal drugs to prevent or treat infection, and management of side effects such as nausea and mouth sores. Tumor lysis syndrome, a chemical imbalance when many leukemia cells die at once, is prevented with fluids and medication. Palliative care teams can help at any stage, not only at the end of life.
Future Perspectives
Research in myeloid leukemia is moving on several fronts at once:
- Menin inhibitors: a newer class of drugs for AML with KMT2A rearrangements or NPM1 mutations, which blocks a protein these leukemias depend on.
- Measurable residual disease (MRD): highly sensitive tests that detect leftover leukemia after treatment are increasingly used to decide who needs a transplant and to catch relapse early.
- Immunotherapy: CAR T-cell therapy and bispecific antibodies are harder to apply in AML than in lymphoid cancers, because AML targets are often shared with healthy blood stem cells, but trials continue.
- Safer transplants: reduced-intensity conditioning and better prevention of graft-versus-host disease are extending transplant to older patients.
- New targets: work on epigenetic regulators and RNA-binding proteins aims to overcome resistance to existing drugs.
For readers new to the field, our introduction to hematology explains the basics behind these therapies.
Key Takeaways
- CML is now a chronic, controllable condition for most patients thanks to TKIs.
- AML treatment is increasingly personalized by genetic testing, with targeted drugs added to chemotherapy.
- Venetoclax combinations have made effective treatment possible for many older or less fit adults.
- Stem cell transplant remains the main curative option for higher-risk AML.
- MRD testing, menin inhibitors, and immunotherapy are shaping the next phase of care for this hematological cancer.
Frequently Asked Questions
What is the standard first treatment for AML?
For fit patients, the standard is intensive induction chemotherapy with cytarabine and an anthracycline, sometimes with a targeted drug added based on mutations. Older or less fit patients often receive venetoclax combined with azacitidine or decitabine instead.
Can CML treatment ever be stopped?
Some patients with a deep, stable molecular response over a long period can stop their TKI under specialist monitoring. Regular PCR tests are essential afterward, because the disease returns in some patients, and restarting treatment usually controls it again.
Is a stem cell transplant always needed for AML?
No. Patients with favorable-risk AML are often treated with chemotherapy alone. Transplant is generally recommended for intermediate or adverse-risk disease, or after relapse, when the benefit outweighs its substantial risks.
Why does genetic testing take time before AML treatment?
Results such as FLT3 status can determine whether a targeted drug should be added from the start. When a patient is stable, waiting a short time for these results allows a more tailored plan; when the situation is urgent, treatment begins straight away.
